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Studies  of  the  action  of sulfonamide  chemotherapy  upon  the  pulmonary 
lesion  of  experimental  pneumococcal  pneumonia  in  rats  have  shown  that 
phagocytosis plays an important part in bringing about the final  destruction 
of pneumococci in the lungs of treated animals (1).  According to present con- 
cepts of immunology, the protective capsule of the pneumococcus renders it 
resistant to phagocytosis (2).  It is generally believed that the fully encapsu- 
lated organism cannot be engulfed by phagocytic ceils unless the surface of the 
capsule is altered by the presence of type-specific antibody (opsonin)  or the 
capsule  itself is  sufficiently injured  to  destroy its  antiphagocytic  properties 
(3-5).  If the phagocytosis of pneumococci is dependent  upon one of these 
two conditions,  there  would appear to be only three likely explanations  for 
the  phagocytic  reaction  demonstrated  in  the  pneumonic  lungs  of  animals 
treated with sulfonamides.  (1)  The sulfonamide drug may injure the capsule 
of the pneumococcus either directly or indirectly and thus promote its phago- 
cytosis.  (2)  The phagocytic reaction may be brought about by the presence 
of natural  or acquired  opsonins  in  the  animal's  serum,  t3)  A  quantity  of 
type-specific antibody sufficient  to opsonize  the pneumococci in the lung may 
accumulate locally in the pulmonary lesion although no opsonin can be dem- 
onstrated at the time in the circulating blood. 
The  experiments reported in the present  paper have  been designed to in- 
vestigate each of these three possibilities. 
Relation  of Injury of the Pneumococcus Capsule to Pkagocylosis 
Pneumococci (A-5 strain) were grown in both rabbit blood broth and serum broth (I per 
cent)  (6)  containing 10 nag. per cent of sulfapyridine.  This concentration of drug caused 
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marked bacteriostasis, as shown by the growth curves in Text-figs. 1 and 2.  Organisms were 
removed from the sulfapyridine broth cultures after 12, 18, 24, and 36 hours and were washed 
repeatedly  in fresh broth; they were then added in various dilutions to tubes of normal, de- 
fibrinated rat blood, and were placed in a slowly rotating incubator according to the method 
of Chandler  and Janeway  (7).  Tests  for phagocytosis  included  (1)  direct  examination  of 
blood films stained with methylene blue after 30 minutes, 1 hour, and 2 hours of incubation, 
and (2) determination of the viability of the organisms by culture at the end of 24 and 48 hours 
,)f incubation. 
In all experiments  the pneumococci which had been exposed  to the  action 
of sulfapyridine  failed  to be either phagocyted or killed  by the  leucocytes in 
the  normal  rat  blood,  t  Since  long exposure  to  the  drug  did  not  render  the 
pneumococcus susceptible  to phagocytosis, it can be concluded that the sulfa- 
pyridine itself does not injure the capsule of the organism sufficiently to promote 
phagocytosis. 
Rdation  of Phagocytosis  to  Possible  Circulating  Opsonins 
Type-specific opsonins might  conceivably account for the  phagocytic reac- 
tion observed in the lungs of animals receiving sulfonamide if immune bodies 
could be detected  in rat  serum either  (1)  as natural  antibody present  in the 
blood of normal rats,  or (2)  as acquired antibody accumulating in the  serum 
during  the  course  of the  experimental  infection.  Repeated  tests  for natural 
antibodies  against  the  A-5  strain  of Type  I  pneumococcus were  made  with 
four~f the most sensitive tests available for the detection of circulating immune 
bodies.  The methods  used  included  (a)  the  standard  mouse  protection  test 
(8),  (b)  the standard  bactericidal  test  (7),  (c)  an in vitro  phagocytic test  (5), 
and  (d)  a  "modified"  mouse  protection  test.  2  In none of the  numerous  ex- 
periments  performed  with  these  four methods  was antibody  detected  in  the 
serum of normal rats. 
Since  the  phagocytic  reaction  seen  in  the  lungs  of  rats  recovering  from 
experimental  pneumonia occurs during the 2nd day of infection, it can be ac- 
counted for by acquired circulating  type-specific opsonins only if these  anti- 
bodies can be demonstrated as early as the 2nd day of the disease.  As shown 
in Table I, type-specific antibodies do not appear in detectable quantity in the 
serum of rats recovering from experimental pneumonia until more than 3 days 
have elapsed. 
As is shown below, normal rat b]ood contains  no demonstrable  type-specific opsonins 
or bactericidal antibody for the strain of pneumococcus used in these tests.  When antibody 
was added to the rat blood, however, pneumococci were promptly phagocyted and destroyed, 
indicating that the phagocytes in the blood were functionally intact. 
2 In the "modified" mouse protection  test, pneumococci in the stationary phase of growth 
(5) were incubated for 4 hours in the test serum to insure opsonization.  The serum-pneumo- 
coccus mixture  was then inoculated  intraperitoneaUy  into mice having a preexisting sterile 
peritonitis  produced  by injection  of starch-aleuronat.  Each mouse received from 1 to 10 
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It is concluded, therefore, that the phagocytosis of pneumococci in the lungs 
of rats recovering from experimental pneumonia is not related either to natural 
or to acquired type-specific opsonins occurring in the blood serum. 
Relation of Phagocytosis to Possible Local Accumulation of Opsonins in the Lung 
Pneumonic  lungs  of  rats  recovering  from pneumococcal  pneumonia  (4th 
and 6th day) were frozen and ground in a ball mill or were minced in a Waling 
blendor and were then extracted with 15 per cent sodium chloride in order to 
split polysaecharide  from  any  antibody which  might  be  present  (9).  The 
polysaccharide was removed by dialysis and the protein precipitate was con- 
centrated  by  dialysis  under  negative  pressure.  All  mouse  protection  tests 
for antibody in such lung extracts were uniformly negative. 
TABLE I 
Mouse Protectlon Tests 
Survival time" of ~fwtal t~ice:l:  Survival time* of prepared retest 
Day of pneumonia on which blood  inoculated with rat serum (0.2 ¢c.)  inoculated with rat serum (0.2 co.) 
was drawn from rats  and pneumococci (10 organisms)  and pneumo¢occi (10 organisms) 
Day 1  ..................... 
Day 2 ..................... 
Day 3 ..................... 
Day 4 ..................... 
Day 7... 
Controls (no serum) ......... 
40 
40 
40 
S 
S 
40 
40  40 
40  40 
40  40 
S  S 
S  S 
40  40 
40  4O 
40  40 
40  40 
S  S 
4-0 
40  40 
4O  4O 
40  40 
S  S 
s  s 
4O 
40  4.0  4O 
40  40  66 
4o 
S  S 
S  S  S 
4O  4O  40 
* Number indicates time that mouse was found dead (hours after inoculation).  S indi- 
cates survival for 1 week. 
~: Tests were done with both normal mice and mice "prepared"  by injection of 0.8  cc. 
of 0.5 per cent sodium nucleinate 48 hours before the test to cause a sterile peritonitis. 
Since efforts to  extract antibody from the  resolving pneumonic lung  were 
unsuccessful, an attempt was made to demonstrate antibody in situ by testing 
for its presence in the pneumonic lesion.  It seemed likely that antibody might 
be present  in  the  lesion  in  sufficient  concentration  to  opsonize pneumococci 
and yet in too small amounts to be detected by the relatively crude methods 
of chemical extraction  (10). 
Rats with Type I  pneumonia were treated with sulfapyridine in  the usual 
manner for 72 hours, at the end of which time all visible pneumococci in the 
lesion had been phagocyted and destroyed (1).  Onto this resolving lesion was 
inoculated intrabronchially by cannula a  second heavy suspension of virulent 
Type I  pneumococci (0.5 to 1.0 ml. of an undiluted 6 hour broth culture) and 
the animals were sacrificed for histological examination of the lungs at intervals 
varying from 30 minutes to 4  hours after the second inoculation.  As shown 
in the accompanying photomicrographs, pbagocytosis of the second inoculum W. BARRY WOOD, yR.,  C. McLEOD, AND E. N. IRONS  381 
of pneumococci begins within 1 hour (Fig. 1) and at the end of 4 hours prac- 
tic.ally all the organisms are found to be within the phagocytic cells (Fig. 2). 
The same results were obtained with animals treated for 96 hours before being 
given a second intrabronchlal inoculation  of pneumococci. 
It was at first assumed that the phagocytic reaction occurring in the resolving 
lesion in the above experiments was due to type-specific opsonins and therefore 
would not occur when a heterologous  type of pneumococcus was used in the 
second  inoculation.  This assumption was  found to be  incorrect,  for when 
Type II pneumococci were inoculated upon a resolving (96 hour) lesion caused 
hya Type I organism (or vice versa)  the same striking phagocytic reaction was 
observed.  Fig. 3 shows the appearance  of the phagocytic cells 4 hours after 
the second inoculation with a heterologous  type of pneumococcus.  It might 
he assumed that phagocytosis of the heterologous  type of pneumococcus was 
due to  the  accumulation of circulating antibodies of the heterologous  type 
during recovery.  Mouse  protection tests, however,  showed that rats recov- 
ering from Type I pneumonia acquired no demonstrable immune bodies to the 
Type II pneumococcus.  It was also suggested that the inoculation  of pneu- 
mococci upon a resolving lesion might cause a very rapid production of anti- 
bodies  corresponding  in  type to  that  of the  second  inoculum.  But mouse 
protection tests done on the serum of rats bled at various intervals after the 
second inoculation revealed no such accelerated  production of immune bodies. 
To illustrate further the lack of type specificity of the phagocytic reaction 
observed  in the resolving pneumonic lesion, an experiment was performed in 
which a Type I pneumonia was produced in the left lung and a Type II pneu- 
monia in the right lung of the same animal.  After 96 hours of sulfonamide 
chemotherapy Type  I  pneumococci  were  inoculated intrabronchially upon 
both lesions.  The photomicrographs  in Fig. 4 show that phagocytosis of the 
organisms was equally striking in the two lungs. 
A sterile pneumonia was produced by the intrabronchial injection of mucin 
alone,  and virulent pneumococci  (6 hour culture) were then inoculated onto 
this resolving lesion.  As illustrated in Fig.  5,  there was observed  the same 
active  phagocytosis of pneumococci  even  though  the  animals had  had  no 
previous  contact  with  the  pneumococcus,  a  The  possibility  that  a  species- 
specific pneumococcal antibody is involved in the phagocytosis  would, therefore, 
appear to be remote. 
Since type-specific antibody is the only immune body known to  opsonize 
virulent encapsulated pneumococci,  the following experiment was  performed 
as a final test of the possibility that type-specific opsonins are the cause of the 
a Because these rats did not receive sulfapyridine the experiment adds additional support 
to the conclusion that the phagocytic reaction in the lung is in no way dependent upon the 
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phagocytic reaction.  Rats recovering from Type II pneumonia (96 hours  of 
chemotherapy) were given an intravenous injection  of an excessively  large 
amount of Type I polysaccharide (10 rag.) just before the intmbronchial inocu- 
lation  of Type  I  pneumococci  upon  the  resolving  lesions.  The  inoculated 
Type I pneumococci were suspended in a high concentration of Type I poly- 
saccharide  (15  rag.  per  cc.).  Inasmuch as pneumococcus  polysaccharide  is 
known to combine with and inactivate homologous type-specific antibody (11), 
the presence of phagocytosis in the lungs of rats so treated with polysaccharide 
(Fig. 6) is strong 6vidence against the hypothesis that type-specific opsonins 
are  responsible  for  the  phagocytosis  observed  in  the  resolving  pneumonic 
lesion. 
From these  observations  it is concluded  that the phagocytosis of pneumo- 
cocci in the lungs is unrelated to the presence of type-specific antibody in the 
pneumonic lesion. 
DISCUSSION 
Early studies  on  the  curative action of sulfapyridine upon pneumococcal 
infections led to the conclusion that the drug exerts a direct action upon the 
capsule of the organism.  From a  study of experimental pneumococcal  peri- 
tonitis in mice, Whitby (12) concluded that "the capsules became swollen and 
crenated and eventually disappeared" as the result of sulfapyridine therapy. 
This conclusion was in accord with the theory of Levaditi and Vaisman  (13), 
who suggested that sulfonamide drugs also prevented the capsulation of hemo- 
lytic streptococci.  In accordance with this theory it mightbe concluded that 
the phagocytosis  of pneumococci  observed  in  the  lungs  of pneumonic rats 
treated with sulfapyridine  was due to a  direct action of the drug upon the 
capsule of the pneumococcus.  However, Whitby's early conclusions were not 
confirmed  by  subsequent  studies  (14).  The  experiments  reported  in  the 
present paper also fail to confirm the view  that sulfapyridine exerts an op- 
sonizing  effect  upon  the  pneumococcus.  Growth  of  the  organism  in  high 
concentrations of sulfapyridine in no way altered its resistance to phagocytosis. 
Hence it can be concluded that the phagocytic reaction that occurs in the lungs 
of animals recovering from experimental pneumonia is due to some factor other 
than injury to the pneumococcus capsule by the drug. 
The sera  of most adult human beings  (4,  15)  as well as those of several 
laboratory animals (16-19) are known to contain natural antibodies against 
many different types of pneumococci.  It has  been  suggested  that natural 
circulating opsonins play an important r61e in the mechanism of recovery from 
pneumococcal  pneumonia and  that  they may even  explain  the  phagocytic 
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however, by the fact that natural antipneumococcal immune bodies are known 
to disappear from the serum of many patients during the active stage of pneu- 
monia and may be absent at the time of recovery (20).  Conclusive disproof 
of the hypothesis is offered by the present experiments  in which the animal 
selected for study was found to possess no natural antibody against the pneu- 
mococcus used.  Though the rat possesses no natural antipneumococcal  op- 
sonins, its lung has been shown to be the seat of an active phagocytic reaction 
which readily destroys the offending bacteria. 
The effective phagocytosis might likewise be explained  by the presence of 
acquired antibody in the blood serum.  There is clinical  evidence,  however 
that patients recovering from pneumonia, either spontaneously or after sulfon- 
amide chemotherapy, not infrequently experience a crisis in the disease several 
days before immune bodies appear in the serum (21-25).  This evidence alone 
is  inconclusive,  for it is  conceivable  that  the crisis  might occur before  ap- 
preciable phagocytosis took place in the lungs.  The present experiments were 
designed to determine the relationship  between the onset of phagocytosis and 
the appearance of antibodies in the serum.  It is clear that phagocytosis begins 
in the lung at least 48 hours before immune bodies can be detected in the serum. 
The phagocytosis observed in the lungs of rats recovering from experimental 
pneumonia cannot, therefore, be accounted for by the presence of either natural 
or acquired antibodies in the serum. 
Although antibody cannot be demonstrated in the serum of rats when they 
first exhibit the pulmonary phagocytic reaction, it is still possible that antibody 
may  be  present in  the  local  pulmonary lesion.  Robertson  (26) observed 
phagocytosis in the lungs of dogs dying of experimental pneumonia, and since 
no antibody could be demonstrated in the serum of these animals, he suggested 
that immune bodies  may be  produced  locally  in  the lungs and  thus cause 
phagocytosis without being present in detectable amounts in the circulating 
blood.  It has been demonstrated also that recently immunized experimental 
animals exhibit an increased resistance to pneumococcal infection several days 
before  immune bodies  can  be  demonstrated in  their serum  (10).  There  is 
considerable doubt, however, as to whether significant amounts of type-specific 
antibody can exist in an unbound state in the pneumonic lung.  Homologous 
type-specific polysaccharide  is known to combine with specific antibody and to 
nullify its effectiveness as an opsonin  (10).  The lungs of patients dying of 
lobar  pneumonia have  been  shown  to  contain huge  quantities of capsular 
polysaccharide  (27), and specific carbohydrate has likewise been demonstrated 
in  the lungs  of dogs  recovering  from experimental pneumonia as long  as 2 
months after recovery (28).  Even if it is assumed that antibody accumulates 
locally in the pneumonic lesion, it apparently does not neutralize all of the 384  MECHANISM  OI RECOVERY  IN  PNE~OCOCCAL  PNEUMONIA.  rrr 
antiphagocytic polysaccharide and therefore cannot be expected to  opsonize 
the pneumococci. 
The present  observations all offer strong evidence against the  hypothesis 
that the phagocytosis is due to the local accumulation of type-specific opsonins 
in the pneumonic lesion. 
SUMMARY 
The phagocytosis which occurs in the lungs of rats receiving sulfonamide is 
due neither to an opsonizing action of the sulfonamides nor to  type-specific 
antibody.  The  evidence  presented  indicates  that  the  destruction  of  the 
pneumococci is brought about by a phagocytic mechanism independent of both 
opsonization and capsular injury. 
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EXPLANATION  OF PLATES 
Sections stained by the Gram-Weigert technique. 
PLATE 15 
FlO. 1.  Phagocytosis of virulent Type I pneumococci (6 hour culture) inoculated 
onto resolving pneumonic lesion of homologous type.  Second inoculum injected intra- 
bronchially after 72 hours of sulfonamide treatment, at which time none of the pneu- 
mococci from the  original  inoculum was still visible (1).  Animal sacrificed  1 hour 
after second inoculation.  ×  945. 
FIc. 2.  Same as Fig. 1, 4 hours after second inoculation.  ×  945. 
FIG. 3.  Phagocytosis of virulent Type II pneumococci (6 hour culture) inoculated 
onto resolving  pneumonic lesion  of hd~rologous type  (Type I).  Second  inoculum 
injected after 96 hours of sulfonamide treatment.  Animal sacrificed  4 hours after 
second inoculation.  ×  945. THE  JOURNAL  OF  EXPERIMENTAL  MEDICINE  VOL,  84  PLATE  15 
(Wood et al.:  Mechanism of recovery in pneumococcal tmeumonia.  III) PLATE 16 
Fla.  4.  Type I pneumonia was produced in the left lung and Type 1I pneumonia 
in the right lung of the same animal.  After 96 hours of sulfonamide chemotherapy 
(when all of the original pneumococci had  been destroyed) Type I  pneumococci (6 
hour  culture)  were  inoculated  intrabronchially  upon  both  lesions.  Photomicro- 
graphs  4 a  (left  lung)  and  4 b  (right  lung)  show  that  phagocytosis  was  equally 
striking in the two lungs.  X 945. 
FIG.  5.  Sterile  pneumonia  was  produced  by  intrabronchial  injection  of  mucin 
alone, and virulent Type I  pneumococci (6 hours culture)  were inoculated onto the 
resolving  lesion  4  days  later.  The  phagocytic reaction  was  active  4  hours  after 
inoculation of pneumococci, although an;mals had  had  no previous known contact 
with pneumococci and received no sulfonamide treatment.  X  945. 
FIG.  6.  Rats recovering from Type II pneumonia (96 hours ef sulfonamide chemo- 
therapy) were given an intravenous injection of Type I polysaccharide (10 rag.) just 
before  the  intrabronchial  inoculation  of Type  I  pneumococci  upon  the  reso!ving 
lesion.  The Type I pneumococci were suspended in a high concentration of Type I 
polysaccharide (50 rag. per cc).  Phagocytosis was striking 4 hours after the second 
inoculum in spite of the fact that pneumococcal polysaccharide is known to combine 
with  and  inactivate  homologous type-specific opsonins.  X  945. THE  JOURNAL  OF  EXPERIMENTAL  MEDICINE  VOL.  8~  PLATE 16 
(Wood et al.:  Mechanism of recovery in pneumoccccal pneumonia.  III) 